Ubs Group Ag Allogene Therapeutics, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 796,491 shares of ALLO stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

796,491

Previous 347,340 129.31%

Holding current value

$1.35 Million

Previous $972,000 74.49%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.84 - $3.22 $826,437 - $1.45 Million	449,151 Added 129.31%	796,491 $1.7 Million
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $97,799 - $164,566	47,019 Added 15.66%	347,340 $972,000
Q2 2024 Aug 13, 2024	SELL	$2.23 - $4.38 $488,102 - $958,694	-218,880 Reduced 42.16%	300,321 $699,000
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $986,977 - $1.9 Million	338,006 Added 186.54%	519,201 $2.32 Million
Q4 2023 Feb 09, 2024	SELL	$2.28 - $3.5 $58,285 - $89,474	-25,564 Reduced 12.36%	181,195 $581,000
Q3 2023 Nov 09, 2023	SELL	$3.17 - $5.96 $286,102 - $537,907	-90,253 Reduced 30.39%	206,759 $655,000
Q2 2023 Aug 11, 2023	BUY	$4.53 - $6.74 $292,189 - $434,736	64,501 Added 27.74%	297,012 $1.48 Million
Q1 2023 May 12, 2023	BUY	$4.92 - $8.21 $475,424 - $793,340	96,631 Added 71.11%	232,511 $1.15 Million
Q4 2022 Feb 08, 2023	SELL	$5.62 - $11.11 $256,249 - $506,571	-45,596 Reduced 25.13%	135,880 $854,000
Q3 2022 Nov 10, 2022	BUY	$10.32 - $17.28 $456,216 - $763,896	44,207 Added 32.2%	181,476 $1.96 Million
Q2 2022 Aug 10, 2022	SELL	$6.78 - $12.28 $580,354 - $1.05 Million	-85,598 Reduced 38.41%	137,269 $1.57 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $498,213 - $995,776	65,126 Added 41.29%	222,867 $2.03 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $193,916 - $362,135	-14,769 Reduced 8.56%	157,741 $2.35 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $2.82 Million - $3.71 Million	134,161 Added 349.84%	172,510 $4.43 Million
Q2 2021 Aug 13, 2021	SELL	$23.49 - $35.8 $1.11 Million - $1.7 Million	-47,409 Reduced 55.28%	38,349 $1 Million
Q1 2021 May 12, 2021	BUY	$25.79 - $39.02 $2.18 Million - $3.3 Million	84,515 Added 6799.28%	85,758 $3.03 Million
Q4 2020 Feb 11, 2021	SELL	$25.24 - $43.45 $5,022 - $8,646	-199 Reduced 13.8%	1,243 $32,000
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $49,768 - $69,103	-1,537 Reduced 51.59%	1,442 $54,000
Q2 2020 Jul 31, 2020	SELL	$18.39 - $54.04 $3,199 - $9,402	-174 Reduced 5.52%	2,979 $128,000
Q1 2020 May 01, 2020	BUY	$18.22 - $28.25 $15,140 - $23,475	831 Added 35.79%	3,153 $62,000
Q4 2019 Feb 14, 2020	SELL	$24.82 - $31.4 $39,836 - $50,397	-1,605 Reduced 40.87%	2,322 $60,000
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $1.48 Million - $1.87 Million	-56,758 Reduced 93.53%	3,927 $107,000
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $1.31 Million - $1.6 Million	51,427 Added 555.49%	60,685 $1.63 Million
Q1 2019 May 14, 2019	BUY	$24.82 - $32.54 $154,777 - $202,919	6,236 Added 206.35%	9,258 $268,000
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $67,995 - $100,632	3,022 New	3,022 $81,000

Others Institutions Holding ALLO

# of Institutions

177

Shares Held

139M

Call Options Held

75.8K

Put Options Held

52.8K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $243M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account